EAU 2021 NMIBC Guidelines
Tumor Characteristics
Classification Pending
Enter tumor status, CIS presence, T-stage, grade, and clinical risk factors to calculate the EAU 2021 Risk Group.
Guidelines & Evidence
Verified
Last Review: 2026
When to Use
Clinical Purpose of EAU Risk Stratification
Non-muscle-invasive bladder cancer (NMIBC) encompasses disease confined to the mucosa (Ta, CIS) and submucosa (T1). It accounts for approximately 75–80% of all new bladder cancer diagnoses. The disease is heterogeneous — some patients are cured by transurethral resection of the bladder tumor (TURBT) alone, while others recur or progress to muscle-invasive disease (T2+), where prognosis is substantially worse. The EAU 2021 risk grouping system was developed to stratify this heterogeneity into four actionable tiers — Low, Intermediate, High, and Very High Risk — each with distinct recommendations for adjuvant intravesical therapy, the need for restaging TURBT (re-TURBT), and surveillance cystoscopy intervals. The 2021 update supersedes the older three-tier EAU system and distinguishes Very High Risk as a discrete category, driven by clinical evidence that this subgroup has unacceptably high progression risk with standard BCG therapy alone.
When to Apply the EAU NMIBC Risk Grouping
All patients with newly diagnosed bladder tumor confirmed by cystoscopy, following adequate TURBT (complete macroscopic resection of all visible lesions)
Before any decision on adjuvant intravesical therapy (single immediate postoperative instillation [SIPI] of chemotherapy, induction BCG, or maintenance BCG)
Before deciding whether re-TURBT is indicated (obligatory in T1 tumors, HG tumors without detrusor in specimen, and some TaHG tumors)
To determine surveillance cystoscopy and upper tract imaging schedule
At recurrence after prior NMIBC treatment — risk group may change at recurrence and dictates whether BCG failure criteria apply (see Very High Risk section)
NOT applicable in muscle-invasive (T2+), metastatic disease, or upper tract urothelial carcinoma (UTUC) — separate staging systems apply
Pathological Staging — Key Definitions for Risk Grouping
| Stage | Definition | Depth of Invasion | Risk Group Relevance | Clinical Notes |
|---|---|---|---|---|
| Ta | Papillary tumor confined to urothelium (mucosa) | Above basement membrane — no lamina propria invasion | Low or Intermediate risk if LG; High risk if HG/G3 with risk factors | Most common presentation (60–70% of new NMIBC). Nearly all papillary exophytic tumors. TaHG is uncommon but critical to recognize (upstage risk substantially). |
| T1 | Tumor invades subepithelial connective tissue (lamina propria) | Penetrates basement membrane into lamina propria, does not reach muscularis propria (detrusor) | High or Very High Risk — lamina propria invasion implies aggressive biology and 20–30% risk of progression to muscle invasion | T1 substaging (T1a: above muscularis mucosae; T1b: into or beyond muscularis mucosae) is being integrated into EAU guidelines as T1b correlates with worse outcomes, though substaging not yet mandatory in 2021 update. |
| CIS (Tis) | Carcinoma in situ — flat high-grade urothelial carcinoma confined to mucosa | Confined to urothelium but cytologically malignant, no exophytic component | High or Very High Risk regardless of papillary tumor grade or stage — CIS alone is High Risk; CIS + T1 HG = Very High Risk | Often invisible on white-light cystoscopy — blue-light (hexaminolevulinate) or narrow-band imaging cystoscopy significantly improves detection. May present as erythematous flat lesion, positive cytology with negative cystoscopy, or incidental finding. |
| Ta multifocal | Multiple papillary tumors present simultaneously (≥ 2 lesions) | Same as Ta (mucosal) | Clinical risk factor — shifts risk group upward (Low → Intermediate or Intermediate → High) | Multifocality implies field cancerization and increased risk of recurrence (OR for recurrence 1.7). Up to 20% of patients with multifocal TaLG will recur within 12 months. |
WHO Grading Systems — 1973 vs 2004/2016
The EAU 2021 guidelines use both grading systems in parallel, as pathology reports globally still reference one or both. The 1973 WHO grading system classifies urothelial tumors as G1 (well differentiated), G2 (moderately differentiated), or G3 (poorly differentiated). The 2004/2016 WHO grading uses a binary system: Low Grade (LG) and High Grade (HG). Approximate concordance: G1 maps to LG; G3 maps to HG; G2 is heterogeneous — most G2 tumors are re-classified as LG, but a subset with cytologic atypia or architectural disorder map to HG. For risk stratification purposes: LG ≈ G1/G2 (low grade behavior); HG ≈ G3 (high grade behavior). The EAU Risk Grouping uses "LG/G1" and "HG/G3" as paired equivalents throughout the stratification criteria.
Clinical Risk Factors — The Three Key Modifiers
| Clinical Risk Factor | Threshold | Rationale / Biological Basis | Impact on Staging | Evidence Quality |
|---|---|---|---|---|
| Age > 70 years | > 70 years at diagnosis | Older patients have higher likelihood of prior urothelial field effects (chronic carcinogen exposure, recurrent infections, prior therapy), reduced immune surveillance, and lower tolerance of intravesical therapy (increased BCG toxicity) | Shifts low-risk TaLG/G1 to Intermediate Risk if single tumor; contributes to High Risk combinations | Multivariable analysis from EORTC database (n > 2,500); independently associated with recurrence (OR 1.4) and progression (OR 1.9) at 5 years |
| Multiple papillary tumors (multifocality) | ≥ 2 simultaneous papillary lesions at initial TURBT | Multifocality reflects urothelial field cancerization — carcinogen exposure (tobacco, aniline dyes, cyclophosphamide) induces widespread genetic instability. Each additional focus increases recurrence probability by 15–20%. | Shifts primary TaLG/G1 from Low to Intermediate Risk. Contributes to High and Very High Risk combinations in T1 and CIS settings. | EORTC risk tables validation; confirmed in multiple single-institution series. Multifocality is the single most potent predictor of recurrence in TaLG disease. |
| Tumor diameter > 3 cm | Largest tumor dimension > 3 cm by cystoscopy or CT estimation | Larger tumors have greater tumor burden, higher probability of incomplete resection at first TURBT (residual disease rate 33–78% for tumors > 3 cm vs 8–15% for < 3 cm), and higher rates of submucosal extension even in Ta tumors. | Contributes to Intermediate and High Risk classification in combination with other factors. A single TaLG > 3 cm in a patient < 70 years with no multifocality is Low Risk only if it is a primary lesion. | EORTC multivariable model; size > 3 cm increases 1-year recurrence risk from 15% to 30% in TaLG. |
Related Scores in Practice
In clinical practice, this assessment is frequently evaluated alongside other validated measures. Depending on the patient's presentation and specific diagnostic requirements, you may also need to utilize the Eortc Risk Tables Nmibc to formulate a comprehensive care plan.
Last Comprehensive Review: 2026